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TGF-beta1 has been shown to induce autophagy in certain cells but whether and how this action is exerted in muscle and
whether this activity relates to TGF-beta1 control of muscle cell differentiation remains unknown. Here, we show that expression
of the autophagy-promoting protein phosphoprotein enriched in diabetes/phosphoprotein enriched in astrocytes (PED/PEA-15)
progressively declines during L6 and C2C12 skeletal muscle cell differentiation. PED/PEA-15 underwent rapid induction upon
TGF-beta1exposureofL6andC2C12myoblasts,accompaniedbyimpaireddifferentiationintomaturemyotubes.TGF-beta1also
induced autophagy in the L6 and C2C12 cells through a PP2A/FoxO1-mediated mechanism. Both the TGF-beta1 effect on
differentiation and that on autophagy were blocked by speciﬁc PED/PEA-15 ShRNAs. Myoblasts stably overexpressing PED/
PEA-15 did not differentiate and showed markedly enhanced autophagy. In these same cells, the autophagy inhibitor
3-methyladenine rescued TGF-beta1 effect on both autophagy and myogenesis, indicating that PED/PEA-15 mediates TGF-beta1
effects in muscle. Muscles from transgenic mice overexpressing PED/PEA-15 featured a signiﬁcant number of atrophic ﬁbers,
accompanied by increased light chain 3 (LC3)II to LC3I ratio and reduced PP2A/FoxO1 phosphorylation. Interestingly, these
mice showed signiﬁcantly impaired locomotor activity compared with their non-transgenic littermates. TGF-beta1 causes
transcriptional upregulation of the autophagy-promoting gene PED/PEA-15, which in turn is capable to induce atrophic
responses in skeletal muscle in vivo.
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The superfamily of transforming growth factor-beta (TGF-
beta) cytokines are ubiquitously expressed and induce a wide
variety of effects ultimately depending on the cell context and
including regulation of cell growth, proliferation, differentia-
tion, adhesion, migration and apoptosis.
1–6 Also, different
members of the TGF-beta superfamily, including the arche-
typal TGF-beta family member TGF-beta1, have been found
to inhibit myogenic differentiation in primary cultures and in
myoblast cell lines from different species.
7–9 These ﬁndings
have evoked considerable translational interest, as inhibitors
of the TGF-beta signaling cascade are currently being
targetted to reduce muscle wasting accompanying both acute
metabolic derangements and chronic disorders such
as cancer, congestive heart failure, sarcopenia, acquired
immunodeﬁciency and long-lasting and poorly compensated
diabetes mellitus.
10
In all of these catabolic conditions, protein breakdown is
enhanced and exceeds protein synthesis, resulting in loss of
muscle mass and myoﬁber atrophy. There is substantial
evidence indicating that autophagic ﬂux is increased during
muscle atrophy due to upregulation or downregulation of
different sets of genes designated atrogenes.
11,12 These
include genes encoding proteins that are degraded when
autophagosomes fuse with lysosomes, such as the micro-
tubule-associated protein 1 light chain 3 (LC3I). The latter is
convertedtoLC3IIduring autophagy,sothattheLC3IItoLC3I
ratio is often taken as representative of autophagy induction.
However, whether autophagy itself causes muscle ﬁber
degeneration remains a debated issue.
13
Although TGF-beta1 has recently been shown to represent
an important regulator of autophagy in liver and mammary
cells,
14 autophagy in the skeletal muscle is peculiar as
compared with that occurring in other metabolically relevant
tissues. During fasting, most tissues show a transient
activation of autophagy. In contrast, skeletal muscle shows
a persistent generation of autophagosomes that continues for
days,
11 suggesting that different mechanisms control autop-
hagosome formation during short or long periods of induced
autophagy. Whether and how TGF-beta1 features auto-
phagy-promoting activity in muscle cells and whether this
activity may lead to impaired myogenesis is unknown.
Phosphoprotein enriched in diabetes/phosphoprotein
enriched in astrocytes (PED/PEA-15) is a 15KDa molecule,
which binds to different signaling proteins thereby regulating
their function and several survival and metabolic transduction
pathways.
15,16 PED/PEA-15 cellular levels are controlled by
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16
which have been shown to be dysregulated in human
disorders including type 2 diabetes. Many type 2 diabetic
individuals feature exagerated expression of PED/
PEA-15,
17,18 leading to impaired insulin action and secretion
and, possibly, contributing to diabetes long-term complica-
tions.
19 Quite recently, evidence has been reported indicating
thatPED/PEA-15 promotesautophagyingliomacellsthrough
a JNK-dependent mechanism,
20 rendering the cells resistant
to starvation and other adverse stimuli. In the present work,
we show that PED/PEA-15 autophagy-promoting action is
necessary for enabling complete TGF-beta1 control of
myogenesis.
Results
Effect of PED/PEA-15 on L6 cell differentiation. Low
serum exposure causes L6 and C2C12 skeletal muscle cells
to spontaneously differentiate in culture with the generation
of multinucleate myotubes.
7–9,21 As previously reported,
7–9
the L6 and C2C12 myotube formation is accompanied by
upregulation of a number of genes including MyoD1,
myogenin and GLUT4. Unexpectedly, however, these
same gene proﬁle studies revealed that expression of the
autophagy regulator PED/PEA-15 underwent progressive
reduction both during L6 and C2C12 cell differentiation
(Figure 1a, left panel). Similar changes occurred in the case
of PED/PEA-15 protein levels (right panel), raising the
possibility that this multifunctional molecule exerts a
previously unidentiﬁed physiological role in myogenesis. To
test this hypothesis further, we have transfected L6 or C2C12
myoblasts with a PED/PEA-15 cDNA, increasing PED/
PEA-15 levels by approximately 10-fold (Figure 1b, top
panel). We then compared differentiation in these cells and in
cells transfected with the empty vector. As shown in Figures
1b and c, PED/PEA-15 overexpression impaired myotube
formation both in L6 and C2C12 and reduced activation of
the myogenesis markers MyoD1, myogenin and GLUT4 by
42-fold in these cell types. At variance, the abundance of
GLUT1 mRNA was 3-fold higher in PED/PEA-15-transfected
as compared with the control cells.
Role of PED/PEA-15 in TGF-beta1 action. To explore the
role of PED/PEA-15 in muscle differentiation in greater detail,
we have further examined its expression in L6 and C2C12
myoblasts upon addition of TGF-beta1 into their culture
medium. Indeed, TGF-beta1 exerts a physiological role in
controlling muscle development and constrains myogenesis
in different cultured skeletal muscle cells.
7–9 Interestingly,
TGF-beta1 exposure enhanced PED/PEA-15 expression by
almost 5-fold upon 6h exposure (Figure 2a) and exhibited a
consistent time- and dose-dependent effect on PED/PEA-15
protein levels as well (data not shown). The effect of TGF-
beta1 on PED/PEA-15 expression was signiﬁcantly reduced
in L6 (or C2C12, data not shown) cells by the SB431542
inhibitor of the TGF-beta1 receptor, in parallel with SMAD3
phosphorylation (Figures 2b and c). Signiﬁcant inhibition of
TGF-beta1 effect was also achieved using a speciﬁc
phosphorothioate antisense of SMAD3 (SMAD3 AS),
indicating that TGF-beta1 stimulates PED/PEA-15 expres-
sion in a TGF-beta1R/SMAD3-dependent manner.
On the basis of MyoD1, Myogenin and GLUT4 mRNA
levels, TGF-beta1 treatment impaired L6 myoblasts differ-
entiation (Figures 3a–c). This effect was largely prevented by
two speciﬁc ShRNAs (ShPED1 and ShPED2), which silence
PED/PEA-15 expressionby 470%(Figures 3a–d). Theeffect
of TGF-beta1 on myotube generation was similarly affected
by the PED/PEA-15 ShRNA (Supplementary Figure 1).
Phosphorylation of PED/PEA-15 was also required for TGF-
beta1-mediated myoblasts differentiation. In fact, in presence
of the PEDS116A mutant, TGF-beta1 failed to reduce MyoD1,
Myogenin and GLUT4 mRNA levels (Figures 4a–d). Thus, in
the L6 skeletal muscle cells, the complete regulatory role of
TGF-beta1 on myogenesis requires the impact of TGF-beta1
signaling on PED/PEA-15. Same results were obtained in
C2C12 (data not shown).
Promotion of autophagy by TGF-beta1 in L6
cells. Current evidence indicates that ﬁne tuning of
autophagy has a major role in enabling differentiation.
11–13
This observation led us to hypothesize that the recently
recognized autophagy-promoting function of PED/PEA-15
20
is necessary for the myogenesis constrain imposed by TGF-
beta1, as TGF-beta1 has also been very recently shown to
induce autophagy in non-muscle cells.
14 FACS analysis of
acridine orange-stained cells revealed that differentiating L6
(or C2C12, data not shown) cells treated with TGF-beta1 for
6 days accumulated acidic vescicular organelles (AVOs, a
prominent feature of autophagy) to a signiﬁcantly greater
extent than control cells (Figure 5a). In parallel, TGF-beta1
treatment signiﬁcantly increased both LC3I to LC3II
conversion and Beclin 1 cell abundance, two known
markers of autophagy activation (Figure 5b). In addition,
exposure of L6 or C2C12 differentiating cells to the
autophagy inhibitor 3-methyladenine led to rescue of the
myotube differentiation markers in the presence of TGF-
beta1 (Figure 5c), indicating that promotion of autophagy by
TGF-beta1 is relevant to the differentiation constrain.
Previous studies revealed that the forkhead transcription
factor FoxO1 regulates the expression of several autophagy-
related genes, including Beclin1 and LC3 and induces
muscle wasting.
22–25 Consistently, exposure of L6 or
C2C12 differentiating cells to TGF-beta1 led to
dephosphorylation of both FoxO1 and of its upstream
regulator, the PP2A serine/threonine phosphatase
(Figure 5d).
PED/PEA-15 promotion of autophagy mediates
TGF-beta1 effect on differentiation in L6 cells. The
overexpression of PED/PEA-15 (10-fold above the
endogenous levels) was sufﬁcient to determine a 10-fold
increase in AVO accumulation, enhanced LC3I to LC3II
conversion and augmentation in Beclin1 abundance (Figures
6a and b). As it is the case for myogenesis, ShPED1 (or
ShPED2, data not shown) vector silencing of endogenous
PED/PEA-15 impaired TGF-beta1 effects on both AVO
accumulation and the autophagy markers (Figures 6c and d).
Moreover, in L6 myoblasts, expression of exogenous
PED/PEA-15 reduced PP2A and FoxO1 phosphorylation,
PED/PEA-15 and skeletal muscle differentiation
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TGF-beta1 effect on their phosphorylation (Figures 6b and d).
At variance, transfection of the PEDS116A mutant did not
elicit any effect on TGF-beta1-mediated autophagy as well
as FoxO1 and PP2A dephosphorylation (data not shown).
Importantly,3-methyladeninetreatmentofL6differentiating
cells stably overexpressing PED/PEA-15 reduced autophagy
to levels similar to those detected in the untransfected cells
and rescued myotube biochemical and morphological differ-
entiation (Figures 7a–c). Same results were obtained in
C2C12 (data not shown). Thus, the autophagy-promoting
function of PED/PEA-15 appeared to mediate the induction
of autophagy and the impaired myogenesis, which follows
TGF-beta1 exposure.
In vivo consequences of skeletal muscle overexpression
of PED/PEA-15. To address the signiﬁcance of these
ﬁndings to skeletal muscle in vivo, we performed
histological analysis of tibialis anterior and quadriceps
muscles from PED/PEA-15 transgenic mice. These animals
Figure1 EffectofPED/PEA-15onL6cellandC2C12differentiation.(a)L6andC2C12cellswereplatedanddifferentiationwasinducedasdescribedunderMaterialsand
Methods. Upon the indicated times in culture, the cells were lysed and protein samples were analysed by western blotting using PED/PEA-15 antibodies and beta-actin for
control.BlotswererevealedbyECLandautoradiography.Alternatively(leftpanel),totalRNAwasobtainedfromthecellsandPED/PEA-15mRNAwasassessedbyreal-time
RT-PCR using beta-actin as internal control. Each bar represents the mean ±S.D. of four independent experiments, each of which was performed in triplicate. (b) In L6 and
C2C12 cells transfected with a cDNA encoding PED/PEA-15 (pcDNAIII-PED) or the empty vector (pcDNAIII), differentiation was induced as described under Materials
and Methods. (c) Differentiated myotubes were then lysed and lysates blotted with PED/PEA-15 antibodies (top panel). Alternatively, total RNA was obtained from the cells
and MyoD1,Myogenin, GLUT4,Glut1 and TGF-beta1 mRNAswere quantitatedby real-time RT-PCR(bottom panel). Values are expressedas % of those in cells transfected
with the empty vector. Each bar represents the mean ±S.D. of four independent experiments in triplicate. Asterisks denote statistically signiﬁcant differences (*Po0.05;
**Po0.01).BrightﬁeldimagesoftheL6andC2C12cells(100  magniﬁcation)transfectedwitheitherthePED/PEA-15cDNAorwiththeemptyvectorupon6daysinculture.
The microphotographs shown are representative of ﬁve other independent sets of observations
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19,26 and feature about
10-fold overexpression of the PED/PEA-15 gene in their
muscles. As shown in Figures 8a–c, hematoxylin–eosin-
and Engel trichrome-stained sections revealed a 10%
increase in atrophic ﬁbers between PED/PEA-15 transgenic
mice and WT (panel a). Rimmed vacuoles (panel b) and
vacuoles with red inclusions (panel c) were also signiﬁcantly
increased in the PED/PEA-15 transgenic muscles. Staining
with speciﬁc antibodies revealed signiﬁcantly higher
expression of LC3 and Beclin1 in muscles form transgenic
compared with those of control mice (Figures 8d and e).
Indeed, muscles from the PED/PEA-15 transgenic mice
revealed a 44-fold increase in the LC3II to LC3I ratio with
similar-sized reduction in phospho-PP2A and phospho-
FoxO1 levels (Figure 9a). MyoD1 and myogenin mRNA
levels were also signiﬁcantly reduced in muscles from the
PED/PEA-15 transgenics (Figure 9b). Whether these
biochemical changes were paralleled by in vivo functional
abnormalities was further analyzed by determining
transgenic mouse traveled distance in an open ﬁeld.
Interestingly, this test revealed a signiﬁcant decrease in
locomotor activity in the PED/PEA-15 transgenic mice
(Figure 9c), suggesting a causal relationship between the
muscle phenotype of these transgenic mice and the control
of muscle development by PED/PEA-15.
Discussion
Skeletal muscle ontogeny and postnatal physiology are
regulated by the TGF-beta family of cytokines in different
animal systems from mice to humans. Signiﬁcant advance-
ment has also been made in the elucidation of the detailed
mechanisms involved in this regulation.
1–6 However, many
aspects of the TGF-beta signaling events leading to its action
on skeletal muscle mass remain unsettled. In the present
work, we have identiﬁed the multifunctional protein PED/PEA-
15 as a key molecule transducing TGF-beta 1 signals and
enabling TGF-beta1 repression of the myogenesis program.
We now report that, in the L6 and in C2C12 skeletal muscle
cells the expression of PED/PEA-15 gene progressively
declines during myogenesis. In addition, exogenous PED/
PEA-15 overexpression inhibits myotubes generation and
differentiation leading us to hypothesize that PED/PEA-15 is
implicatedinmechanismscontrollingmyogenesis.Indeed,we
have further found that exposure to TGF-beta 1 restrains
differentiation and, simultaneously, enhances PED/PEA-15
Figure2 EffectofTGF-beta1onPED/PEA-15expressioninL6andC2C12cells.(a)Skeletalmusclecellswerestimulatedwith5ng/mlTGF-beta1fortheindicatedtimes.
Total RNA was then isolated from the cells and the levels of PED/PEA-15 mRNA were assessed by real-time RT-PCR using beta-actin as internal control. Alternatively, the
cellsweretreatedwith0.1mMoftheTGF-beta1receptorinhibitorSB431542ortransientlytransfectedwith200nMSMAD3phosphorothioateantisense(SMAD3AS)followed
bystimulationwith5ng/mlTGF-beta1,asdescribedunderMaterialsandMethods.ThecellswerethenharvestedforassessmentofPED/PEA-15mRNAlevels(b)orwestern
blotted with speciﬁc PED/PEA-15, phospho-SMAD3 (pSMAD3) and SMAD3 antibodies (c). Blots were revealed by ECL and autoradiography using beta-actin as a loading
control. The autoradiograps shown are representative of four independent experiments. Bars represent the mean ±S.D. of four independent experiments. Asterisks denote
statistically signiﬁcant differences (*Po0.05; **Po0.01; ***Po0.001)
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PEA-15 protein into the cell. This effect appears to be
achieved via the TGF-beta1R/SMAD3 pathway activation,
as inhibition or silencing of these key molecules signiﬁcantly
impaired PED/PEA-15 upregulation by TGF-beta1. Similar
effects have been noted also in primary myoblasts from WT
and TgPED mice (data not shown). Different Smad response
elements were identiﬁed in the PED/PEA-15 promoter region
whose occupancy increased following L6 cell exposure to
TGF-beta1 (data not shown), suggesting regulation of PED/
PEA-15 gene by TGF-beta1 signaling. Importantly, we show
that ShRNAs silencing of endogenous PED/PEA-15 and
abrogation of PED/PEA-15 phosphorylation at seryl 116
largely prevented TGF-beta1 action on muscle cell differ-
entiation, indicating that PED/PEA-15 exerts a major role in
mediating the myogenesis control exerted by TGF-beta1. The
(TGF-beta1-mediated) phosphorylation status of PED/PEA-
15 also may have a central role in this process because non-
phosphorylated PED/PEA-15 lacks the capability to induce
myogenic gene expression.
Despite intensive investigation, how TGF-beta1 inhibits
myogenesis has been only partially elucidated. Smad3 is the
key mediator,
27,28 as it physically interacts with both MyoD
and MEF2C.
29 The presence of PED/PEA-15 in this network
was unanticipated and led us to explore its signiﬁcance to
TGF-beta1 action in greater detail. Autophagy is a dynamic
process in which intracellular membrane structures, the
autophagosomes, sequester proteins and organelles for
degradation.
30 Autophagy is implicated in homeostasis and
cell-size regulation in multiple organs both during normal
development and under stress conditions.
31,32 Recently, the
role of autophagy in muscle differentiation has attracted much
attention.
11–13 However, it remains unclear whether autop-
hagy is detrimental and part of the mechanisms that induce
muscle degeneration, or whether it is a compensatory
mechanism for cell survival. Both TGF-beta1 and PED/
PEA-15 have been reported to activate autophagy in several
tissues, though not in skeletal muscle.
14,20 In the present
report, we describe that both of these molecules exert an
autophagy-promoting action in the L6 skeletal muscle cells.
Importantly, we obtained evidence that PED/PEA-15 promo-
tion of autophagy mediates the effect of TGF-beta1 on
differentiation in the L6 cells. Indeed, although silencing of
the endogenous PED/PEA-15 blocked TGF-beta1-induced
autophagy, inhibition with 3-methyladenine in L6 cells
overexpressing PED/PEA-15 reduced autophagy to levels
comparable to the untransfected cells and rescued myo-
genesis.Alltogether,theseﬁndingsledustoconcludethatthe
Figure 3 The role of PED/PEA-15 in TGF-beta1-impaired myogenesis in L6 cells. L6 myoblasts were transfected either with a scrambled or a PED/PEA-15 ShRNAs and
maintained in culture enabling them to differentiate for the indicated times and in the presence or the absence of 5ng/ml TGF-beta1. Total RNA preparations were then
obtained from the cells and the levels of MyoD1 (a), Myogenin (b), Glut4 (c) and PED/PEA-15 mRNA (d) were quantitated by real-time RT-PCR analysis, using beta-actin as
internal standard. Each bar represents the mean ±S.D. of four independent experiments in which each reaction was performed in triplicate. Asterisks denote statistically
signiﬁcant differences (
#Po0.01 for differences between Sc at day 6 or 9 and Sc at day 0; *Po0.05; **Po0.01; ***Po0.001)
PED/PEA-15 and skeletal muscle differentiation
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Cell Death and Differentiationautophagy-promoting function of PED/PEA-15 mediates both
theautophagyinductionandtheimpairedmyogenesiscaused
by TGF-beta1. These effects have been obtained also in
primary myoblasts from WT and TgPED mice (data not
shown).
Very recent evidence indicates a direct role of the forkhead
transcription factors (FoxOs) in regulating the cellular
mechanisms responsible for autophagy activation and im-
pairment of myoblasts differentiation. Foxo1 ablation in
C2C12 cells or in mice increases the levels of MyoD, whereas
forced expression of FoxO1 upregulates autophagic and
atrophic responses in muscle cells.
12,22–25,33 Indeed, FoxOs
have been shown to promote the expression of different
autophagy-related genes. These include BECLIN1, ATG8,
Gabarapl1, ATG12, ATG4B and VSP34.
21–24 FoxO1, in turn,
is highly regulated at the post-transcriptional level. Depho-
sphorylation at Ser256 by the Ser/Thr phosphatase PP2A
activates FoxO1, inducing its nuclear translocation.
34,35
Interestingly, PP2A has been shown to undergo activation in
response to TGF-beta1 in different cell types.
36 Here, we
show that, in the L6 cells, full activation of the PP2A/FoxO1
signaling by TGF-beta1 requires PED/PEA-15. Indeed,
(i) forcing PED/PEA-15 expression is sufﬁcient to dephospho-
rylate PP2A and FoxO1, thus driving the nuclear translocation
of FoxO1; and, (ii) PED/PEA-15 silencing signiﬁcantly
attenuates the effect of TGF-beta1 on the PP2A/FoxO1-
transduced signal.
34–36 How PED/PEA-15 impacts on PP2A
has not been completely demonstrated yet. However, data
from our own and other laboratories indicate that PED/PEA-
15 induces PKC-delta in different cell types, including the L6
cells. PKC-delta, in turn, enhances PP2A activity,
37,38
indicating that it might induce PP2A in the L6 cell, as well.
These ﬁndings may have in vivo relevance as PP2A and
FoxO1 activation accompanied by higher levels of autophagy
markers and AVOs were also detected in skeletal muscle
tissue from transgenic mice overexpressing PED/PEA-15.
These changes were paralleled by detectable muscle atrophy
and decreased locomotor activity in these animals. Indeed,
there is now evidence that the FoxO family of transcription
factors has a major transcriptional role in the muscle atrophy
accompanying a number of disorders, including type 2
diabetes. In the type 2 diabetic individual, resistance to
insulin in the PI3K/AKT signaling cascade is believed to
represent a major mechanism responsible for muscle atrophy
and sarcopenia, as impaired AKT function releases the brake
on FoXO1 activity.
34,35 However, increased TGF-beta1 levels
have also been reported in type 2 diabetes.
19 Here, we show
that TGF-beta1 upregulates PED/PEA-15 and may contribute
Figure 4 The role of PED/PEA-15 phosphorylation in TGF-beta1-impaired myogenesis in L6 cells. L6 cells transfected with the empty (pcDNAIII) or the PED/PEA-15
(pcDNAIII-PED) vector or the PED/PEA-15 S116A mutant (PEDS116A) were maintained in culture enabling them to differentiate for the indicated times and in the presence or
theabsenceof5ng/mlTGF-beta1.TotalRNApreparationswerethenobtainedfromthecellsandthelevelsofMyoD1(a),Myogenin(b),Glut4(c)andPED/PEA-15mRNA(d)
were quantitated by real-time RT-PCR analysis, using beta-actin as internal standard. Each bar represents the mean ±S.D. of four independent experiments in which each
reaction was performed in triplicate. Asterisks denote statistically signiﬁcant differences (
#Po0.01 for differences between Sc at day 6 and Sc at day 0; **Po0.01;
***Po0.001)
PED/PEA-15 and skeletal muscle differentiation
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individuals with type 2 diabetes.
17,18 This increased expres-
sion has no effect on PI3K/AKT signaling. Thus, TGF-beta1
induction of PED/PEA-15, may represent a previously
unrecognized mechanism leading to FoxO1 activation,
impaired myoblasts differentiation, muscle atrophy and
decreased muscle mass, which accompany long-lasting
diabetes. This hypothesis is currently under active investiga-
tion in our laboratory.
Inconclusion,inthepresentreport,wehaveidentiﬁedPED/
PEA-15 as novel molecule in the TGF-beta1 signaling
network of the muscle cell. In this cell types, transcriptional
upregulation of the PED/PEA-15 gene by TGF-beta1 induces
autophagic responses, atrophy and might contribute to the
decreased muscle mass accompanying long-lasting type 2
diabetes.
Materials and Methods
Materials. Media, sera, antibiotics for cell culture and the lipofectamine reagent
were from Invitrogen (Grand Island, NY, USA). The PED/PEA-15 polyclonal
antibody and pcDNAII-PED/PEA-15 vector have been previously described.
19
The actin, pSMAD3, SMAD3, PP2A, pPP2A and Beclin1 antibodies were from
Figure 5 TGF-beta1 effect on autophagy in L6 and C2C12 cells. (a) Differentiating L6 cells were treated with 5ng/ml TGF-beta1 as described under Materials and
methods. After 6 days in culture, the cells were stained with acridine orange and AVO accumulation was determined by ﬂow cytometric analysis. Calculated percentages
representthered-positivecellsintheupperquadrants(R10andR11).FITCLin,greencolorintensity;PETexasRedArea,redcolorintensity.Thoseshownarerepresentative
of four independent experiments. Alternatively (b and d), L6 and C2C12 cells were lysed as described under Materials and Methods and western blotted using PED/PEA-15,
Beclin1, LC3 I, LC3 II, phospho-Tyr307-PP2A, phospho-Ser256-FoxO1 or FoxO1 antibodies. Blots were revealed by ECL and autoradiographs, using beta-actin as loading
control. The autoradiographs shown are representative of three independent experiments. (c) L6 and C2C12 cells were plated and exposed for 72h to 5ng/ml TGF-beta1 in
theabsenceorthepresenceof1mM3-methyladenine(3MA).Upon6daysofdifferentiation,totalRNAwasisolatedandthelevelsofMyoD1,MyogeninandGlut4mRNAwere
quantitated by real-time RT-PCR analysis, with each reaction performed in triplicate. Bars represent the mean ±S.D. of four independent experiments. Asterisks denote
statistically signiﬁcant differences (*Po0.05; **Po0.01; ***Po0.001)
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antibodieswerefrom UpstateBiotechnolgy (Lake Placid,NY, USA); LC3antibodies
were from Cell Signaling Technology, Inc. (Beverly, MA, USA). TGF-beta1 cytokine
was from PeproTech, Inc. (Rocky Hill, NJ, USA). The phosphorothioate oligo-
nucleotides antisense sequences were as follows: SMAD3 AS: 50-GCAGGATGG
ACGACAT-30; SMAD3 S: 50-GGAGTCAGACTGACGA-30. Protein electrophoresis
reagents were purchased from Bio-Rad (Richmond, VA, USA), western blotting
and ECL reagents from Amersham Biosciences (Arlington Heights, IL, USA).
PED/PEA-15 ShRNA vectors and all other chemicals were from Sigma (St. Louis,
MO, USA).
Cell culture procedures and transfection. The L6 muscle and C2C12
cells were grown in Dulbecco’s modiﬁed Eagle’s medium (DMEM) supplemented
with 10% fetal bovine serum, 10000m/ml penicillin, 10mg/ml streptomycin, and
2% l-glutamine in a humidiﬁed CO2 incubator and differentiated as described
in Caruso et al.
39 Stable transfection of the PED/PEA-15 cDNA and transient
transfection of antisense oligonucleotides or PED/PEA-15 S116A mutant
(PEDS116A) were performed by the lipofectamine method according to the
manufacturer’sinstructions(Invitrogen).Forthesestudies,70to80%conﬂuentcells
were washed twice with Optimem (Invitrogen) and incubated for 8h with 5mgo f
plasmid construct, ShRNA vectors or antisense oligonucleotides (200nM) and
45 to 60ml of lipofectamine reagent. The medium was then replaced with DMEM
with 10% (vol/vol) fetal bovine serum and cells further incubated for 15h before
being assayed. In transient transfection studies, the medium was then replaced
with DMEM with 10% fetal bovine serum and cells were further incubated for
15h before being assayed. For experiments with stably transfected cells, individual
Figure 6 PED/PEA-15 autophagy-promotingactivitymediatesTGF-beta1actionon L6 celldifferentiation. L6cellsstablyoverexpressing PED/PEA-15(pcDNAIII-PED)or
transfected with the empty vector (pcDNAIII) were plated and enabled to differentiate as described under Materials and Methods. AVO accumulation was determined as
outlined in Figure 4 (a). The one shown is representative of four independent experiments. (b) Alternatively, the cells were lysed and 100 microgram protein samples were
analyzedby western blotting using the indicatedantibodies.Blots wererevealed by ECL and autoradiography, using beta-actinas loading control. The autoradiograph shown
is representative of three independent experiments. (c) Differentiated myotubes were transiently transfected with either the ShPED/PEA-15 RNA (Sh PED/PEA-15) or
a scrambled RNA (Sc) and then exposed to 5ng/ml TGF-beta1. AVO accumulation was assessed as outlined in Figure 4. The one shown is representative of three
independent experiments. (d) Alternatively, the cells were lysed and protein samples were analyzed by western blotting using the indicated antibodies. Blots were revealed
by ECL and autoradiography, using beta-actin as loading control. The autoradiograph shown is representative of four independent experiments
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effective dose, 0.8mg/ml). The expression of PED/PEA-15 by the individual clones
was quantitated by western blotting. In all transfection studies, the efﬁciency
was consistently between 65 and 75%. Transfection efﬁciency of antisense
oligonucleotides was estimated as 45±10% by co-transfection with green
ﬂuorescent protein.
TGF-beta1 treatment in differentiating L6 and C2C12 cells. When
cells reached B90% of conﬂuence (day 0), the medium was replaced with the
differentiation-promoting medium (DMEM 2% fetal bovine serum), and the cells
stimulated with TGF-beta1 (5ng/ml) for 6 or 9 days (cytokine added on days 1, 3, 5
and 1, 3, 5, 7). Control cells were maintained in differentiation medium. The cells
were then harvested and lysates were analyzed by western blotting, real time PCR,
FACS analysis on days 6 and 9.
Mouse generation and phenotyping. The transgenic mice overexpres-
sing PED/PEA-15 have been previously described.
25 These mice were fertile. Their
body weight is comparable to that of their wild-type littermates.
25 All procedures
described below were approved by the Institutional Animal Care and Utilisation
Committee. Animals were kept in a 12-h dark–light cycle and had free access to
standard diet. Mice chosen for experimentation were randomly selected from each
box of mice housed in groups of three to four.
Open-ﬁeld exploration. Free exploration in a square arena (walls made of
transparent plexiglas 50 50cm, 40cm high) was allowed as previously
described.
40 Mice were enabled to explore for 5min the open-ﬁeld apparatus,
placed in an experimental room with several large-scale environmental visual cues
and homogeneous illumination. Exploratory behavior was recorded with a high
deﬁnition digital camera and on-line videotracking was implemented using custom
software written in Matlab environment. Total traveled distance was taken as an
index of locomotor activity.
Muscle dissection and immunohistochemical examination.
Skeletal muscle specimens (tibialis anterior or quadriceps) from PED/PEA-15
transgenic or control mice were processed according to Paciello et al.
41 Brieﬂy,
dissected muscles were frozen in isopentane pre-cooled in liquid nitrogen and
Figure 7 3-methyladenine rescues differentiation in PED/PEA-15-overexpressing L6 cells. L6 myoblasts stably overexpressing PED/PEA-15 were plated and
differentiated in culture as described under Materials and Methods. Seventy two hours before the experiment, the cells were exposed to 1mM 3-methyladenine (3MA).
AVO accumulation was then assessed as outlined under Figure 4 (a). The ﬁgures shown are representative of four independent experiments. Alternatively, total RNA was
obtainedbythecellsfollowedbyquantitationofMyoD1,Myogenin,GLUT4andGLUT1mRNAlevelsbyRT-PCR,usingbeta-actinasinternalstandard(b).Dataarepresented
as % of the levels measured in control cells. Bars represent the mean ±S.D. of four independent experiments in which each reaction was performed in triplicate. Asterisks
denote statistically signiﬁcant differences (**Po0.01; ***Po0.001). (c) Brightﬁeld images (100 ) of L6 cells stably transfected with either the PcDNAIII-PED vector or the
empty PcDNAIII vector in the absence or the presence of 3-methyadenine. The microphotographs shown are representative of three additional experiments
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haematoxylin and eosin (HE), Engel trichrome, or cytochrome C oxidase.
For immunohistochemical examination, frozen sections (6mm) were ﬁxed in
acetone at 41C for 5min, then blocked for endogenous peroxidase in 0.3% H2O2
in methanol for 20min. Muscle sections were further incubated with mouse
monoclonal antibodies against LC3 (dilution 1:50) and BECN1 (dilution 1:50)
overnight at 41C. Slides were washed three times with PBS, incubated with
biotinylated anti-rabbit and labeled streptavidin biotin (LSAB kit; DakoCytomation,
Glostrup, Denmark) for 30min, followed by incubation with streptavidin conjugated
to horseradish peroxidase (LSAB Kit; DakoCytomation, Denmark). Color
Figure 8 Histological and immunohistochemical analysis of skeletal muscles from PED/PEA-15 transgenic mice. Sections from skeletal muscles (tibialis anterior) from
6-month-old transgenic mice and non-transgenic littermates (control; WT) were stained with either hematoxylin-eosin (H/E; a and b) or engel-trichrome (c) or immunostained
with LC3 or Beclin1 (BECN1) antibodies (d, e). The arrows in the microphotographs (40 ) indicate atrophic muscle ﬁbers with basophilic cytoplasm (a), small rimmed
vacuoles (b), vacuoles with red inclusions (c), decoration with LC3 (d) and Beclin1 (BECN1; e) antibodies. The microphotographs shown are representative of ﬁndings
observations in six transgenic and eight non-transgenic animals
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(DakoCytomation, Denmark) treatment. Sections were counterstained with Mayer’s
haematoxylin. In the corresponding negative control section, the primary antibody
was either omitted or replaced with normal mouse serum.
Tissue and cell lysates and western blot analysis. Tissue samples
were homogenised in a Polytron (Brinkman Instruments, Westbury, NY, USA) in
20ml T-PER reagent (Pierce, Rockford, IL, USA) per gram of tissue according
to the manufacturer’s instructions. After centrifugation at 5000 g for 5min,
the supernatant fractions were collected. Cells were solubilised in lysis buffer
(50mmol/l HEPES, pH 7.5, 150mmol/l NaCl, 10mmol/l EDTA, 10mmol/l Na4P2O7,
2mmol/l Na3VO4, 100mmol/lNaF, 10%(vol/vol) glycerol,1% (vol/vol) TritonX-100,
1mmol/l PMSF, 10mg/ml aprotinin) for 1h at 41C and lysates were centrifuged at
5000 g for 20min. Total homogenates were separated by SDS-PAGE and
transferred to 0.45mm Immobilon-P membranes as previously described.
20 Upon
incubation with primary and secondary antibodies, immunoreactive bands were
detected by ECL according to the manufacturer’s instructions.
Real-time RT-PCR analysis. Total cellular RNA was isolated from muscles
of wild-type and PED/PEA-15 transgenic mice using a commercial kit (RNeasy;
Qiagen, Hilden, Germany) and according to the manufacturer’s instructions. Tissue
or cell RNA (1mg) was reverse-transcribed using Superscript III Reverse
Transcriptase (Invitrogen). PCR reactions were analysed using SYBR Green
mix (Invitrogen). Reactions were performed using Platinum SYBR Green qPCR
Super-UDGandamulticolourreal-timePCRdetectionsystem(CyclerIQ; Bio-Rad).
All reactions were performed in triplicate and b-actin was used as an internal
standard. Primer sequences were as follows: TGF-beta1 (forward) 50-ATACG
CCTGAGTGGCTGTCT-30, (reverse) 50-TGGGACTGATCCCATTGATT-30; b-actin
(forward) 50-GCGTGACATCAAAGAGAAG-3, (reverse) 50-ACTGTGTTGGCATAG
AGG-30, MyoD1 (forward) 50-TCGACTCACCAGACCTGCGCT-30, (reverse) 50-CTT
GCAGGCCCACAGCAAGC; myogenin: (forward) 50-ACTCCCTTACGTCCATCG
TG-30, (reverse) 50-CAGGACAGCCCCACTTAAAA-30, Glut4: (forward) 50-CAGAA
GGTGATTGAACAGAG-30, (reverse) 50-AATGATGCCAATGAGAAAGG-30; Glut1:
(forward) 50-GGGAATGTCCTCATCTTGGA-30, (reverse) 50-TGAGGCTCTGTGTG
GTTCTG-30.
Quantiﬁcation of acidic vesicular organelles with acridine
orange. Autophagy in the L6 cells was assessed as previously described.
42
Brieﬂy, acidic vescicular organellles (AVOs) were quantiﬁed by acridine orange
staining. For these studies cells were treated as necessary for each individual
experiment and then gently detached with 0.05% trypsin–EDTA followed by 1.0mg/
ml acridine orange staining for 15min at room temperature. Stained cells were then
analyzed on a FACS cytometer (DakoCytomation, Carpinteria, CA, USA) and the
Summit V4.3 software (DakoCytomation).
42
Statistical methods. Data were analysed with Statview software (Abacus
Concepts, Piscataway, NJ, USA) by one-factor analysis of variance. P-values of
o0.05 were considered statistically signiﬁcant.
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